Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company ...

Core Insights - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases without FDA-approved treatments [1][3] - The company will present at two upcoming healthcare investor conferences, highlighting its commitment to engaging with investors [1][2] Company Overview - Founded by veterans in rare disease drug development, Palvella is dedicated to creating novel therapies for patients with serious, rare genetic skin diseases [3] - The company is developing a pipeline of product candidates using its patented QTORIN™ platform, with a focus on lifelong genetic skin diseases [3] - Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is currently in Phase 3 and Phase 2 clinical trials for specific conditions [3] Upcoming Events - Wes Kaupinen, the CEO, will present at the Cantor Global Healthcare Conference on September 4, 2025, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [2] - Live webcasts of the presentations will be available on Palvella's website, with archived replays accessible for approximately 90 days [2]